Skip to main content

Updating Our Biogen Targets as It Soars on Alzheimer Drug Approval

Traders who went long BIIB on our April recommendation should continue to hold those shares.
Comments

We reviewed the charts and indicators of Biogen (BIIB) on April 16 and wrote that "Traders could go long BIIB here and on strength while risking to $255. The $340 area is our first price objective." 

Prices soared sharply higher on Monday as traders reacted to approval for its Alzheimer drug, so some new targets and stop loss recommendations are needed. 

In this updated daily bar chart of BIIB, below, we can see that prices exploded sharply higher. Prices are well above the 50-day and 200-day moving averages. The On-Balance-Volume (OBV) line has turned sharply higher and so has the Moving Average Convergence Divergence (MACD) oscillator.  

Image placeholder title

In this weekly bar chart of BIIB, below, we can see that prices have broken out over several years of highs. The weekly OBV line has turned up sharply and the MACD oscillator is bullish.  

Image placeholder title

In this daily Point and Figure chart of BIIB, below, we can see that prices reached and exceeded a $403 price target. 

Image placeholder title

In this weekly close only Point and Figure chart of BIIB, below, we see that the software is projecting the $869 area as a potential price target. 

Image placeholder title

Bottom line strategy: Traders who went long BIIB on our April recommendation should continue to hold those shares. Raise stops to your purchase price. The $869 area is our long-term price target. 

Employees of TheStreet are prohibited from trading individual securities.